Biotechnology
Commented by Fabian Lorenz on February 4th, 2026 | 08:50 CET
Yesterday +10%! Top news drives shares of Evotec, Novo Nordisk, and CHAR Technologies!
Evotec shares jumped, climbing more than 10% as analysts pushed the stock higher. Does this signal that the turnaround is finally happening, or does Deutsche Bank still have the final say? Strong news also for CHAR Technologies: the Canadian company is launching commercialization of its unique technology for producing biochar and renewable natural gas substitutes from biogenic waste materials. For the expansion, it has secured strong partners, including steel giant ArcelorMittal and the Canadian BMI Group. And what is Novo Nordisk doing? The Danish company presented positive study results for its successor to Wegovy. However, analysts are not exactly thrilled.
Read
Commented by André Will-Laudien on February 4th, 2026 | 07:10 CET
Starting signal! Biotech sector benefits from rotation! Keep an eye on Evotec, Bayer, Vidac Pharma, and BioNTech
The stock market has started 2026 on a positive note. The mining and commodities sector recently proved that return opportunities are not limited to the technology sector, with several stocks doubling in price and a few even increasing tenfold. A breath of fresh air is needed, because other sectors also want to enjoy the stock market spring. Life science stocks have indeed taken a break for almost three years. But now they are back! After a long period of silence, selected companies are showing the first signs of a technical recovery. For investors with a penchant for opportunities and timing, now is the time to rethink old strategies and realign portfolios. In cancer research, recent breakthroughs in personalized immunotherapies have significantly increased the prospects of success for clinical trials. We take a closer look.
Read
Commented by Armin Schulz on February 3rd, 2026 | 07:05 CET
Zinc boom, turnaround, and biotech growth: How to profit with Pasinex Resources, Puma, and Evotec
In volatile markets, investors are looking for exceptional opportunities. Three companies stand out in this regard. A commodities company with exceptional zinc projects, a sporting goods manufacturer undergoing radical transformation, and a biotech pioneer with a unique platform model. The combination of momentum, strategic turnaround, and long-term growth promises attractive return opportunities. We analyse the promising prospects of Pasinex Resources, Puma, and Evotec.
Read
Commented by Nico Popp on January 30th, 2026 | 07:25 CET
The hunt for the cancer pill from BioNTech & Co.: Why Eli Lilly's billion-dollar bet is a wake-up call for Vidac Pharma
It is one of the oldest rules in the biotech sector: when the big pharmaceutical companies can no longer grow on their own, they open their coffers. The latest billion-dollar deal between US giant Eli Lilly and Dresden-based startup Seamless Therapeutics is more than just a headline – it is a wake-up call for the entire industry. Eli Lilly, now one of the most valuable companies in the world, is desperately seeking innovations to secure its pipeline beyond its booming weight-loss injections. This hunger for new mechanisms of action inevitably focuses attention on small, specialized companies researching revolutionary approaches. In this environment, Vidac Pharma is becoming the focus of strategic investors. The Company is working on an approach that is as elegant as it is radical: it aims to starve cancer rather than poison it by manipulating its metabolism. While Eli Lilly and BioNTech are spreading their billions across a wide range of areas, Vidac is delivering precisely the kind of specialized "deep science" that is often lacking in the pipelines of the big players.
Read
Commented by Fabian Lorenz on January 29th, 2026 | 07:00 CET
Puma takeover is becoming more concrete! Should investors buy Evotec and Silver Viper shares next?
Takeover speculation has been swirling around Puma for some time. Now it has become more tangible: Anta has secured a 29% stake in the German sporting goods group, paying EUR 35 per share. However, the euphoria on the stock market is limited. Are there better opportunities for investors to profit from takeover speculation? One candidate in the hot silver market is Silver Viper. The Company is pushing ahead with exciting projects in Mexico. Its recent capital increase met with strong demand, and a financially powerful potential buyer already has a foot in the door. And what about Evotec? The perennial takeover candidate is still not gaining momentum. That said, the biotech company is benefiting from the sale of one of its own holdings, which is expected to bring in around USD 160 million.
Read
Commented by André Will-Laudien on January 26th, 2026 | 07:30 CET
Biotech and life sciences are booming, and now Mercosur is joining the fray! Bayer, MustGrow, Novo Nordisk, and BioNxt Solutions in focus
The 2026 stock market year has a few surprises in store for investors. In addition to a quick resolution to the Greenland dispute, the Mercosur trade agreement with several South American countries is also moving forward. This agreement is particularly significant for the agricultural industry. This global sector of human supply is increasingly characterized by regulatory pressure, which is effectively ending the use of many synthetic pesticides and fertilizers. This development is forcing established agricultural companies to integrate effective biological alternatives into their portfolios faster than planned. In this environment, MustGrow Biologics is positioning itself as a strategic technology provider whose active ingredients have already been validated by leading market players. An expanded sector view also covers the life sciences industry with the protagonists Bayer, Novo Nordisk, and BioNxt. Up 50% in just a few weeks, here they are!
Read
Commented by Fabian Lorenz on January 26th, 2026 | 01:35 CET
BASF under PRESSURE! BUY RECOMMENDATIONS for BioNTech and WashTec shares!
Market leadership, increased efficiency, dividends, and share buybacks - all good reasons to buy WashTec shares. Analysts at M.M. Warburg share this assessment. Their earnings estimates for the coming years may even be too conservative. Unfortunately, nothing about BASF is conservative; rather, it is disappointing. The chemical company has once again failed to meet analysts' forecasts. Its strong free cash flow is based on lower investments, which is also not a good sign. How are analysts reacting? BioNTech is facing a groundbreaking year. Analysts see potential for share price growth. News from the bulging product pipeline is likely to have a significant impact on the share price.
Read
Commented by Nico Popp on January 23rd, 2026 | 07:15 CET
Revolution in agricultural chemistry: How MustGrow Biologics is benefiting from the plight of Bayer and Corteva
Global agriculture is at a historic turning point, driven less by a belief in technological progress than by regulatory necessity. For decades, global food security has been based on synthetic pesticides and fertilizers, but that era is rapidly coming to an end. Authorities from Brussels to California are tightening the screws and banning established active ingredients one after the other because their ecological collateral damage is no longer tolerated. For the agricultural giants, this poses an existential threat: their full warehouses are in danger of becoming worthless if they do not find effective biological alternatives quickly enough. In the current extremely hectic environment in industry, which is characterized by billion-dollar acquisitions and strategic alliances, new power structures are emerging. While Corteva Agriscience is aggressively buying market share with its chequebook and Bayer is pushing ahead with its portfolio restructuring, the Canadian company MustGrow Biologics has carved out a position that is considered the "sweet spot" in the industry. The Company is the technology partner whose active ingredients have already been validated and licensed by the market leaders.
Read
Commented by André Will-Laudien on January 19th, 2026 | 07:20 CET
Black Monday: Despite Greenland disputes, tariffs, and Mercosur, biotech is on the rise! Bayer, Vidac Pharma, BioNTech, and Novo Nordisk in focus
The stock market has had a very volatile start to 2026. Now, due to the unresolved Greenland issue, punitive tariffs are even being reintroduced for European countries that wish to stick with the Danish administration. Questions of international law did not impact the stock market in any of the conflicts of 2025. What usually receives a lot of attention, however, are shrinking margins caused by artificial tariffs. Just as the EU had been patting itself on the back over the Mercosur agreement, the next Trump-style threat is looming. The biotech sector is advancing steadily and with considerable momentum. Can the life sciences leaders outperform the DAX?
Read
Commented by Nico Popp on January 14th, 2026 | 07:20 CET
Targeting cancer metabolism: Why Bayer and Pfizer are restructuring - and why Vidac Pharma is filling a scientific gap
The investment year 2026 marks a decisive turning point for the global biotechnology and pharmaceutical sector. After a period of macroeconomic uncertainty, we are witnessing a renaissance in the life sciences, driven by two fundamental forces: the urgent need for big pharma players to replace their expiring patents with innovation, and the scientific breakthrough of novel mechanisms of action in agile biotech small caps. While industry giants such as Pfizer and Bayer are attempting to steer their cumbersome tankers onto a new course through massive restructuring, the as-yet little-noticed biotech company Vidac Pharma is delivering the technological innovation the market is looking for. With an approach that directly addresses cancer metabolism and reverses the "Warburg effect," which has been known for almost a century, Vidac is positioning itself as a disruptive force in oncology and dermatology. For investors, this constellation offers a rare opportunity: to observe the stability of the giants while betting on the explosive potential of a technological innovator that analysts say is massively undervalued.
Read